Monographie - Carmustine

viimane versioon :
19/11/2024

Carmustine

keemiline struktuur

Kaubanduslikud nimed erinevates maades

Preparaatide nimed on näitlikud ja abianete sisaldus võib erineda sõltuvalt riigist ja laborist

Becenun	Brasiilia
Bicnu	Ameerika ühendriigid, Austraalia, Hispaania, Iirimaa, Iraan, Kanada, Kolumbia, Kreeka, Maroko, Maroko, Mehhiko, Prantsusmaa, Rumeenia, Suurbritannia, Sveits, Tšiili, Tuneesia, Ungari, uus-Meremaa
Bodacler	Argentiina
Carmubris	Austria, Iraan, Saksamaa
Carmustina Grey	Maroko
Carmustina Perulab	Maroko
Carmustine Baxter	uus-Meremaa
Carmustine Obvius	Austria, Belgia, Bulgaaria, Hispaania, Holland, Horvaatia, Iirimaa, Island, Luksemburg, Norra, Poola, Portugal, Prantsusmaa, Rootsi, Rumeenia, Saksamaa, Slovakkia, Sloveenia, Soome, Suurbritannia, Taani, Tšehhi, Ungari
Nitrourean	Hispaania
Nitrumon	Belgia, Iraan, Luksemburg

Viited : Carmustine

	tüüp	avaldamine
3	ajaleht	Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
81	ajaleht	Trissel LA, Martinez JF. Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 672-678.
84	ajaleht	Trissel LA, Martinez JF. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 495-499.
99	ajaleht	Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
146	ajaleht	Hadji-Minaglou-Gonzalvez MF, Gayte-Sorbier A, Airauto CB, Verdier M. Effects of temperature, solution composition, and type of container on the stability and absorption of carmustine. Clin Ther 1992 ; 14: 821-824.
169	ajaleht	Trissel LA, Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1993 ; 50: 2359-2363.
182	ajaleht	Trissel LA, Gilbert DL, Martinez JF. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 56-60.
244	ajaleht	Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913.
249	ajaleht	Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
307	ajaleht	Trissel LA, Martinez JF. Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1792-1799.
334	ajaleht	Trissel LA, Tramonte SM, Grilley BJ. Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 988-992.
335	ajaleht	Trissel LA, Bready BB, Kwan JW, Santiago NM. Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 402-406.
492	ajaleht	Trissel LA, Parks NPT, Santiago NM. Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2186-2189.
715	ajaleht	Colvin M, Hartner J, Summerfield M. Stability of carmustine in the presence of sodium bicarbonate. Am J Hosp Pharm 1980 ; 37: 677-678.
837	ajaleht	Fredriksson K, Lundgren P, Landersjo L. Stability of carmustine - kinetics and compatibility during administration. Acta Pharm Suec 1986 ; 23: 115-124.
905	ajaleht	Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017.
1410	ajaleht	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.
1423	ajaleht	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
1501	ajaleht	Beitz C, Bertsch T, Hannak D, Schrammel W, Einberger C, Wehling M. Compatibility of plastics with cytotoxic drug solutions - comparison of polyethylene with other container materials. Int J Pharm 1999 ; 185: 113-121.
1520	Labor	Etude de stabilité des médicaments en Ecoflac® B Braun 2001
1622	ajaleht	Favier M, De Casanove F, Coste A, Cherti N, Bressolle F. Stability of carmustine in polyvinyl chloride bags and polyethylene-lined trilayer plastic containers. Am J Health-Syst Pharm 2001 ; 58: 238-241.
2146	ajaleht	Trissel LA, Xu QA, Baker M. Drug compatibility with new polyolefin infusion solution containers. Am J Health-Syst Pharm 2006 ; 63: 2379-2382.
3314	Labor	Carmustine (Bicnu®) – Résumé des caractéristiques du produits Bristol Myers Squibb 2011
4762	ajaleht	Knoll L, Kraemer I, Thiesen J. Physicochemical stability of carmustine-containing medicinal products after reconstitution and after dilution to ready-to-administer infusion solutions stored refrigerated or at room temperature EJHP 2023 ; 30, 1: 11-16.

Mentions Légales